Comparing overall survival outcomes of patients treated with immunotherapy + chemotherapy, or chemotherapy + radiation for non-small cell lung cancer (NSCLC)

Files

Authors

Sukhmani Singh, Oakland University William Beaumont School of Medicine Student
Ishmael Jaiyesimi, Beaumont Health

Description

Traditionally, non-small cell lung cancer has been treated with chemotherapy or surgery, and remained first line treatment until around 2015 when PDL-1 immune checkpoint immunotherapy was introduced and for many patients where it become the standard first line treatment. A few research studies comparing outcome differences between patients receiving immunotherapy versus patients who did primarily chemotherapy as first line treatment indicate increased survival benefit, however, as immunotherapy is still relatively new, longer term survival benefit and analysis of other factors is continuing to be delineated.

Publication Date

5-2023

Keywords

non-small cell lung cancer

Recommended Citation

Singh S, Jaiyesimi I. Comparing overall survival outcomes of patients treated with immunotherapy + chemotherapy, or chemotherapy + radiation for non-small cell lung cancer (NSCLC). Poster presented at: Oakland University William Beaumont School of Medicine Embark Capstone Colloquium; 2023 May; Rochester Hills, MI.

Comments

The Embark Capstone Colloquium at the Oakland University William Beaumont School of Medicine, Rochester Hills, MI, May, 2023.